Benchling, the leading life sciences R&D cloud, has raised $ 200 million in Series E funding led by Sequoia Capital Global Equities and is joined by Altimeter Capital, Byers Capital and Elad Gil. Existing investors participated including Thrive Capital, Benchmark, Menlo Ventures, Alkeon Capital, ICONIQ, Lux Capital, Spark Capital and Lead Edge Capital.
The company will use this funding to aggressively invest in product development and global expansion to support corporate clients, the statement said.
“Recent breakthroughs in biology have the potential to transform the world just like computers and the Internet. We rely on scientists to rewrite the drugs we take, the foods we eat, and the fuels that power our lives. We’re excited to partner with Benchling, who are building the core software infrastructure for the scientists who are redefining the world,” Said Patrick Fu , Managing Partner of Sequoia Capital Global Equities.
Since its launch in 2012, more than 300,000 scientists and 1,000 R&D organizations around the world have adopted Benchling’s cloud platform to manage massively complex experimental data sets and optimize R&D processes. Benchling’s clients – including Gilead Sciences, Sanofi, Regeneron Pharmaceuticals, Corteva Agrisciences, Sana Biotechnology, and more – rely on the company’s suite of cloud applications to design DNA, collaborate on experiments , automate data capture, manage search flows, and enable rapid decision-making, all with the goal of getting products to market faster.
“Sana focuses on engineering genes and cells with the goal of creating new drugs that not only treat diseases, but also, if possible, cure them. It is a complex and interdisciplinary work where each scientist must enter, store and analyze immense amounts of data. Benchling has essential technology that allows Sana’s global R&D teams to focus on developing our platforms and pipeline, setting up the right automation, designing the right experiences, and finding the right experiences. information that resides in our data. Said Steve Harr, co-founder and CEO of Sana.
In January, Benchling announced that it had doubled its annual recurring revenue (ARR) for the fourth year in a row, while adding more than 150 customers in industries such as medicine, food, agriculture, materials, consumer goods and energy. Several Benchling companies have delivered life-saving COVID-19 antibody treatments in record time. Keen to bring Benchling to the world’s largest biotechnology centers to support its core customers, the company also opened its EMEA headquarters in Zurich , Switzerland.
“The past year has proven the impact biotechnology can have on the world. It’s exciting to see our customers at the center of the development of everything from life-saving therapies for COVID-19, to products that are more sustainable for our planet. This funding will allow us to provide more products, solutions and services that scientists around the world ultimately need to solve some of humanity’s greatest challenges. Commented Sajith Wickramasekara, CEO and co-founder of Benchling.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.